
Peter Burgard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7499488/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 1: the initial presentation. Journal of Inherited Metabolic Disease, 2015, 38, 1041-1057.	3.6	186
2	The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 2: the evolving clinical phenotype. Journal of Inherited Metabolic Disease, 2015, 38, 1059-1074.	3.6	175
3	Proposed recommendations for diagnosing and managing individuals with glutaric aciduria type I: second revision. Journal of Inherited Metabolic Disease, 2017, 40, 75-101.	3.6	173
4	Use of guidelines improves the neurological outcome in glutaric aciduria type I. Annals of Neurology, 2010, 68, 743-752.	5.3	147
5	Efficacy and outcome of expanded newborn screening for metabolic diseases - Report of 10 years from South-West Germany *. Orphanet Journal of Rare Diseases, 2011, 6, 44.	2.7	128
6	Biallelic Mutations in NBAS Cause Recurrent Acute Liver Failure with Onset in Infancy. American Journal of Human Genetics, 2015, 97, 163-169.	6.2	110
7	Recurrent acute liver failure due to NBAS deficiency: phenotypic spectrum, disease mechanisms, and therapeutic concepts. Journal of Inherited Metabolic Disease, 2016, 39, 3-16.	3.6	92
8	Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 2 – From screening laboratory results to treatment, followâ€up and quality assurance. Journal of Inherited Metabolic Disease, 2012, 35, 613-625.	3.6	88
9	Crossâ€sectional observational study of 208 patients with nonâ€classical urea cycle disorders. Journal of Inherited Metabolic Disease, 2014, 37, 21-30.	3.6	62
10	Impact of age at onset and newborn screening on outcome in organic acidurias. Journal of Inherited Metabolic Disease, 2016, 39, 341-353.	3.6	60
11	Age at disease onset and peak ammonium level rather than interventional variables predict the neurological outcome in urea cycle disorders. Journal of Inherited Metabolic Disease, 2016, 39, 661-672.	3.6	52
12	Neonatal mortality and outcome at the end of the first year of life in early onset urea cycle disorders—review and metaâ€analysis of observational studies published over more than 35 years. Journal of Inherited Metabolic Disease, 2016, 39, 219-229.	3.6	50
13	Allelic phenotype values: a model for genotype-based phenotype prediction in phenylketonuria. Genetics in Medicine, 2019, 21, 580-590.	2.4	48
14	Impact of Diagnosis and Therapy on Cognitive Function in Urea Cycle Disorders. Annals of Neurology, 2019, 86, 116-128.	5.3	42
15	Long-term Outcomes of Individuals With Metabolic Diseases Identified Through Newborn Screening. Pediatrics, 2020, 146, .	2.1	37
16	Transatlantic combined and comparative data analysis of 1095 patients with urea cycle disorders—A successful strategy for clinical research of rare diseases. Journal of Inherited Metabolic Disease, 2019, 42, 93-106.	3.6	35
17	Living with an inborn error of metabolism detected by newborn screening—Parents' perspectives on child development and impact on family life. Journal of Inherited Metabolic Disease, 2014, 37, 189-195.	3.6	34
18	Biochemical markers and neuropsychological functioning in distal urea cycle disorders. Journal of Inherited Metabolic Disease, 2018, 41, 657-667.	3.6	31

Peter Burgard

#	Article	IF	CITATIONS
19	Newborn screening by tandem mass spectrometry for glutaric aciduria type 1: a cost-effectiveness analysis. Orphanet Journal of Rare Diseases, 2013, 8, 167.	2.7	30
20	Evaluation of dietary treatment and amino acid supplementation in organic acidurias and urea ycle disorders: On the basis of information from a European multicenter registry. Journal of Inherited Metabolic Disease, 2019, 42, 1162-1175.	3.6	30
21	Behavioural and emotional problems, intellectual impairment and healthâ€related quality of life in patients with organic acidurias and urea cycle disorders. Journal of Inherited Metabolic Disease, 2016, 39, 231-241.	3.6	29
22	Networking Across Borders for Individuals with Organic Acidurias and Urea Cycle Disorders: The E-IMD Consortium. JIMD Reports, 2015, 22, 29-38.	1.5	26
23	Issues with European guidelines for phenylketonuria. Lancet Diabetes and Endocrinology,the, 2017, 5, 681-683.	11.4	26
24	Decreased plasma l-arginine levels in organic acidurias (MMA and PA) and decreased plasma branched-chain amino acid levels in urea cycle disorders as a potential cause of growth retardation: Options for treatment. Molecular Genetics and Metabolism, 2019, 126, 397-405.	1.1	26
25	Multifactorial modulation of susceptibility to l-lysine in an animal model of glutaric aciduria type I. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 768-777.	3.8	21
26	Newborn Screening for Vitamin B6 Non-responsive Classical Homocystinuria: Systematical Evaluation of a Two-Tier Strategy. JIMD Reports, 2016, 32, 87-94.	1.5	19
27	Newborn Screening Programmes in Europe, Arguments and Efforts Regarding Harmonisation: Focus on Organic Acidurias. JIMD Reports, 2016, 32, 105-115.	1.5	17
28	Diagnosis and therapeutic monitoring of inborn errors of creatine metabolism and transport using liquid chromatography–tandem mass spectrometry in urine, plasma and CSF. Gene, 2014, 538, 188-194.	2.2	16
29	Development and Psychometric Evaluation of the MetabQoL 1.0: A Quality of Life Questionnaire for Paediatric Patients with Intoxication-Type Inborn Errors of Metabolism. JIMD Reports, 2017, 37, 27-35.	1.5	15
30	Impairment of cognitive function in ornithine transcarbamylase deficiency is global rather than domainâ€specific and is associated with disease onset, sex, maximum ammonium, and number of hyperammonemic events. Journal of Inherited Metabolic Disease, 2019, 42, 243-253.	3.6	15
31	Determinants of Plasma Docosahexaenoic Acid Levels and Their Relationship to Neurological and Cognitive Functions in PKU Patients: A Double Blind Randomized Supplementation Study. Nutrients, 2018, 10, 1944.	4.1	12
32	Impact of glycogen storage disease type I on adult daily life: a survey. Orphanet Journal of Rare Diseases, 2021, 16, 371.	2.7	12
33	A cross-sectional controlled developmental study of neuropsychological functions in patients with glutaric aciduria type I. Orphanet Journal of Rare Diseases, 2015, 10, 163.	2.7	10
34	An Integrated clinical pathway for diagnosis, treatment and care of rare diseases: model, operating procedures, and results of the project TRANSLATE-NAMSE funded by the German Federal Joint Committee. Orphanet Journal of Rare Diseases, 2021, 16, 474.	2.7	7
35	On being an editor, reviewer, and author—different sides of the same coin. Journal of Inherited Metabolic Disease, 2019, 42, 1-2.	3.6	6
36	In vivo monitoring of urea cycle activity with 13C-acetate as a tracer of ureagenesis. Molecular Genetics and Metabolism, 2016, 117, 19-26.	1.1	5

Peter Burgard

#	Article	IF	CITATIONS
37	High blood pressure, a red flag for the neonatal manifestation of urea cycle disorders. Orphanet Journal of Rare Diseases, 2019, 14, 80.	2.7	4
38	Transatlantic combined and comparative data analysis of 1095 patients with urea cycle disorders—a successful strategy for clinical research of rare diseases. Journal of Inherited Metabolic Disease, 2019, 42, 93.	3.6	4
39	Differences of Phenylalanine Concentrations in Dried Blood Spots and in Plasma: Erythrocytes as a Neglected Component for This Observation. Metabolites, 2021, 11, 680.	2.9	3
40	A holistic approach to the patients/ Families with inborn errors of metabolism. Medycyna Wieku Rozwojowego, 2020, 24, 65-72.	0.2	3
41	Response. Pediatric Research, 2007, 61, 134-135.	2.3	0
42	Urea Cycle Disorders in the US and Europe – Evidence-based Clinical Outcomes Derived from Two Decades of Experience with Prospective Registry Studies. , 2019, 50, .		0
43	William L.Nyhan, Georg F.Hoffmann. Atlas of inherited metabolic diseases (Hardcover and eâ€Book)4th ed. Boca Raton: <scp>CRC</scp> Press, Taylor & Francis Group, 2020, 855 p., \$175; £120, â,¬124. <scp>ISBN</scp> â€13: 9781138196599. (With contributions from Aida I. Alâ€Aqeel and Bruce A. Barshop) Iournal of Inherited Metabolic Disease. 2021. 44. 284-284.	3.6	0